Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

13th Annual PDA Global Conference on Pharmaceutical Microbiology

The Future of Pharmaceutical Microbiology: Small World, Big Opportunities
Oct 15 - Oct 17, 2018 |
Oct 17, 2018 |
Bethesda North Marriott Hotel & Conference Center | Bethesda, MD
  • Conference
  • Western Hemisphere Events
Exhibition: October 15-16
Post-Workshop: October 17-18
Courses: October 18-19
Add event to: ICal Outlook Google Calendar
Speaker Biographies

The 13th Annual PDA Global Conference on Pharmaceutical Microbiology is designed to meet the unique needs of pharmaceutical microbiologists and interdisciplinary scientists involved in manufacturing and regulating the pharmaceutical industry. It also provides excellent opportunities to network, interact, and share with and learn from industry experts and professionals from around the world.

This “best in class” Conference will feature an exciting agenda that encompasses a wide variety of issues pharmaceutical microbiologists face and work in partnership to solve daily. A theme of collaboration is woven throughout the Conference, focusing on how we work together to solve highly complex problems and develop novel, compliant, and robust solutions to ensure products are of the highest quality for patients. The “Ask the Experts” interactive session returns by popular demand!

Hear presentations at concurrent sessions from global regulatory and industry experts who will share recent case studies and current trends in the field of pharmaceutical microbiology. Hot topics include:

 

  • Quality Management for the Microbiology Laboratory
  • Updates from USP
  • Innovation in Pharmaceutical Microbiology
  • Data Integrity – Current Regulatory Perspective
  • Manufacturing Challenges – The Future of Biotech

In addition, PDA will host an exhibition of leading bio/pharmaceutical companies who will showcase new technologies and trends for pharmaceutical microbiology strategies. And don’t miss the poster presentations highlighting the latest research and developments in this exciting field! Lunch, refreshment breaks, and the Networking Reception will provide a relaxed environment to view posters, visit vendors, and interact with others to discuss topics from the day’s presentations.

Attend this Conference for the unique opportunity to contribute to future advancements in pharmaceutical microbiology.

Contact

Brooke Schneider, CMP
Manager, Programs
Tel: (301) 656-5900 ext. 111
Email: schneider@pda.org

Registration Customer Care
Tel: +1 (301) 656-5900 ext. 115
Email: registration@pda.org

Exhibition Inquiries
David Hall
Vice President, Sales 
Tel: +1 (240) 688- 4405
Email: hall@pda.org

Course Inquiries
Stephanie Ko
Senior Manager, Lecture Education 
Tel: +1 (301) 656-5900 ext. 151
Email: ko@pda.org

Sunday, October 14

3:00 p.m. – 7:00 p.m.
Registration Open

Monday, October 15

7:00 a.m. – 5:30 p.m.
Registration Open

7:00 a.m. – 8:00 a.m.
Continental Breakfast

8:00 a.m. – 9:45 a.m.
P1: The New Frontier of Personalized Medicine: Regulatory Expectations and Microbiological Challenges
Moderator: Kim Sobien, Principal Sterility Assurance Engineer, PETNET Solutions | A Siemens Company

Imagine using your own body’s cells to cure cancer – the idea has recently been made tangible and has been shown to be successful with new discoveries in the field of immuno-oncology. CAR T (Chimeric Antigen Receptor T-Cell) therapy is a novel cellular therapy that supercharges a patient’s own immune system T-cells and programs them to attack designated cancer cells in the body. Significant challenges with facility design, room classification, manufacturing, testing, and regulatory approval have been brought forth as several of these personalized “living drug” therapies have achieved commercialization. This opening plenary session will explore CAR T product manufacturing challenges from an industry perspective and discuss regulatory challenges for commercialization as well as the use of non-compendial microbiology methods.

8:00 a.m. – 8:15 a.m.
Welcome and Opening Remarks from Conference Co-Chair
Kim Sobien,
Principal Sterility Assurance Engineer, PETNET Solutions | A Siemens Company

8:15 a.m. – 8:45 a.m.
Regulatory Challenges to CAR T Commercialization
Yoko Momonoi, Director, Regulatory CMC, Celgene

8:45 a.m. – 9:15 a.m.
Kimberly L. Schultz, Biologist, CBER, FDA (Invited)

9:15 a.m. – 9:45 a.m.
Questions and Answers/Discussion

9:45 a.m. – 10:15 a.m.
Refreshment Break

10:15 a.m. – 11:45 a.m.
P2: Current Regulatory Updates
US Moderator: Julie Barlasov-Brown, MBA, Associate Director Sterile and Microbiology QA, Merck & Co., Inc.

10:30 a.m. – 11:00 a.m.
Inspection Trends and Revision of EU GMP Annex 1
Andrew Hopkins, Senior GMDP Inspector, MHRA

11:00 a.m. – 11:30 a.m.
Common Inspection Trends
Justin A. Boyd, 
Investigator, ORA, FDA

11:30 a.m. – 12:00 p.m.
Questions and Answers/Discussion

11:45 a.m. – 1:30 p.m.
Grand Opening of Exhibit Hall with Lunch and Poster Presentations

11:45 a.m. – 7:00 p.m.
Exhibit Hall Open

1:30 p.m. – 3:30 p.m.
Concurrent Sessions

A1: The Trouble with Sterility
Moderator: Edward Tidswell, PhD, Executive Director, Microbiology QA, Merck & Co., Inc.    

Sterility is an absolute and binary concept – we categorize therapeutics either sterile or non-sterile. Yet the modality of imparting sterility, sterile manufacturing, and the method of proving sterility remain challenging and possibly one of the greatest potential risks to patient safety. Regulatory expectations, compliance observations, and the cadre of contemporary microbiological tools all used to assure sterility will be discussed to provide a picture of how to avoid trouble with sterility.         

1:30 p.m. – 2:00 p.m.
Stephen E. Langille, PhD, Acting Division Director, Division of Microbiology Assessment, CDER, FDA

2:00 p.m. – 2:30 p.m.
The Problem with Sterility Part 1: Aseptic Processing, The Things We Don’t Talk About (Enough)
Hal Baseman, Chief Operating Officer, ValSource LLC

2:30 p.m. – 3:00 p.m.
Industry Perspective on Sterilization

3:00 p.m. – 3:30 p.m.
Questions and Answers/Discussion

B1: Novel Products, Methods, and Manufacturing Processes
Moderator: Irving Ford, Head of CAR-T QC Laboratories, Celgene

The challenges raised by new products, test methods, and manufacturing processes present great opportunities for innovative approaches in microbiology. The introduction of these new elements is changing the way that we think of microbiology, and forcing the industry and regulators to look at new approaches for process control and product release. This session will explore a novel process, test method, and product to provide unique insights into how the future is quickly becoming the present.

1:30 p.m. – 2:00 p.m.
Process Development and Manufacturing: Current and Future Challenges
Vienna Lo, Principal Scientist, Novartis

2:00 p.m. – 2:30 p.m.
The Monocyte Activation Test (MAT) for Pyrogen Detection
Devon Kleindienst, Research Scientist II, Bristol-Myers Squibb

2:30 p.m. – 3:00 p.m.
Microbiological Considerations for Drug Products Derived from Cannabis and Cannabis Components
Marla Stevens-Riley, PhD, Quality Assessment Lead (Acting)/Master Microbiology Reviewer, CDER, FDA

3:00 p.m. – 3:30 p.m.
Questions and Answers/Discussion

3:30 p.m. – 4:15 p.m.
Refreshment Break and Poster Presentations in Exhibit Hall

4:15 p.m. – 5:45 p.m.
Concurrent Sessions

A2: Microbial Control
Moderator: Eric J. Ward, MBA, Director of Quality Assurance, Boston Analytical

The external environment to a manufacturing process presents a significant source of microorganisms. The potential for microbial ingress from the external environment poses a great challenge for microbial control. This session will focus on controlling a process “from the outside in,” through case studies on equipment contributions and use of EM data to protect a process prior to microbial ingress. The goal of the knowledge sharing will be to incorporate elements into your own microbial control strategies and to improve programs for the future.

4:15 p.m. – 4:45 p.m.
What’s in Your Equipment?
Cheryl Essex, Head of Biologics Microbiological Control, Sanofi

4:45 p.m. – 5:15 p.m.
Bioburden Intensity: An Integrated Approach to Environmental Monitoring Data Trending
Austin W. Kuo, Principal Research Scientist - Sterility Assurance, Eli Lilly and Company

5:15 p.m. – 5:45 p.m.
Questions and Answers/Discussion

B2: Small Mold: Big Problem! Case Studies on Mold in a Manufacturing Facility
Moderator: Ebony Arrington, MS, Pfizer Global Supply, Production Operations, Central Support Manager, Pfizer Biotech

In the wide diversity of the microbial world, mold represents a relatively small portion of the possible overall contaminants. However, the presence of mold within a pharmaceutical manufacturing facility creates the need for heightened awareness and response commensurate with the risk that it poses to the process and ultimately the patient. In this session, two case studies will be presented related to the presence of mold either in the environment or in the process of a pharmaceutical manufacturing facility. The impact and response to the situations will be explored to provide insight into the prevention of future recurrence.

4:15 p.m. – 4:45 p.m.
Case Study of an Environmental Contamination
Brian Lloyd, PhD, Senior Validation Engineer/Clinical Manufacturing Scientist, Pfizer

4:45 p.m. – 5:15 p.m.
Antimicrobial Effectiveness Test Failure: A Case Study for Nasal Spray Product
Mark P.J. Nabuurs, BASc Medical Microbiology, Merck & Co./Merck Sharpe & Dohme

5:15 p.m. – 5:45 p.m.
Questions and Answers/Discussion

5:45 p.m. – 7:00 p.m.
Networking Reception in Exhibit Area

Tuesday, October 16

7:00 a.m. – 5:30 p.m.
Registration Open

7:00 a.m. – 8:30 a.m.
Continental Breakfast

7:15 a.m. – 8:15 a.m.
Breakfast Roundtable
Moderator: Julie Barlasov-Brown, MBA, Associate Director Sterile and Microbiology QA, Merck & Co., Inc.  

8:30 a.m. – 10:00 a.m.
P3: Live Plenary Simulcast from Berlin, Germany


9:45 a.m. – 4:00 p.m.
Exhibit Area Open

10:00 a.m. – 10:45 a.m.
Refreshment Break, Poster Presentations and Passport Raffle in Exhibit Hall

10:45 a.m. – 12:15 p.m.
Concurrent Sessions

A3: Environmental Monitoring
Moderator: Christine Sherman, Director, Global Microbiology and Aseptic Network, Takeda

In order to assure control of manufacturing facilities, environmental monitoring (EM) programs are critical to evaluate the effectiveness of disinfection programs, operator’s aseptic practices, and the engineering controls in place which provide appropriate conditions for manufacture. These programs generate large amounts of data which can make it difficult to determine the best focus of valuable resources. This session will highlight a case study which provides guidance and tools to evaluate personnel gowning data to assess trends and risks. The second case study evaluated the impact of facility changes on sterility assurance and how to determine the most efficient and effective EM performance qualification after modification of the facility.

10:45 a.m. – 11:15 a.m.
Leveraging Gown Monitoring Data to Improve Employee Performance
Joe McCall, SM (NRCM), Technical Service Specialist, STERIS Life Sciences and Jennifer Longstaff, Manufacturing Manager, Aseptic, Bausch + Lomb

11:15 a.m. – 11:45 a.m.
A Case Study of Environmental Monitoring Performance Qualification (EMPQ) Risk Analysis
Frederic B. Ayers, Consultant Scientist, Eli Lilly and Company

11:45 a.m. – 12:15 p.m.
Questions and Answers/Discussion

B3: Biotech Products
Moderator: Bo Chi, Microbiologist, CDER, FDA

Microbial control and sterility assurance during manufacture of biotech products are critical to ensure product quality and patient safety. In this session, FDA and industry will present microbial control strategies and case studies in the context of current challenges encountered by the biotech industry.

10:45 a.m. – 11:15 a.m.
Microbiology and Biologic Manufacturing are Interdependent!
Jean Stuckey, Senior Principal Microbiologist, Patheon Biologics, LLC, part of Thermo Fisher Scientific

11:15 a.m. – 11:45 a.m.
Current Challenges for Biotech Products
Reyes Candau-Chacon, PhD, Quality Assessment Lead, Division of Microbiology Assessment, Branch IV, CDER, FDA

11:45 a.m. – 12:15 p.m.
Questions and Answers/Discussion

12:15 p.m. – 1:15 p.m.
Exhibitor Roundtable Luncheon
Exhibitors will be seated at designated tables and will be available for informal discussion with attendees. Exhibit Hall will be closed during this time.

1:15 p.m. – 3:15 p.m.
Concurrent Sessions

A4: Risk Identification, Assessment, and Mitigation
Moderator: Yeissa M. Chabrier-Roselló, PhD, Microbiology Reviewer, CDER, FDA

A microbiological risk assessment is the scientifically-based process to estimate the likelihood of exposure to a microbial hazard and the resulting impact from this exposure. While the overall tools for quality risk management have been well described (ICH Q9), the practical applications for microbiology continue to present opportunities. This session will present three unique case studies on microbiological risk identification, assessment, and mitigation. It will include real-life perspectives on reactive microbiological risk assessment reports, improvements in aseptic processing to prevent microbial contamination, and manufacturing situations where the shelf life of the product influences the need to build risk reduction into the overall manufacturing processing. This session will emphasize the importance of design with a risk in mind for manufacturing operations upstream and downstream of the final drug product.

1:15 p.m. – 1:45 p.m.
Specific Problems and Advice Associated with Writing Microbiological Risk Assessment Reports for Pharmaceutical/OTC/Medical Device Raw Material/Component/Finished Product Contamination
Dennis E. Guilfoyle, PhD, Senior Director, Microbiology Regulatory Compliance, Johnson & Johnson

1:45 p.m. – 2:15 p.m.
Case Study on Quality Risk Management
Mitchell B. Garber, RPh, Director, Clinical Global Supplies Sterile, GlaxoSmithKline (Invited)

2:15 p.m. – 2:45 p.m.
Risk Reduction in a Novel Aseptic Manufacturing Process
Jessica G. Chiaruttini, PhD, Microbiologist, CDER, FDA

2:45 p.m. – 3:15 p.m.
Questions and Answers/Discussion

B4: Predictably Irrational Microbiology
Moderator: MaryEllen E. Usarzewicz, MS, Parenteral Manufacturing Support Lead, Analytical & Bioanalytical Operations, Microbiology, Bristol-Myers Squibb

Despite best efforts at performing testing in a consistent, predictable fashion, the nature of microbiology is such that the living organisms sometimes do not provide rational results. Predictability also includes the repetitive nature of performing an action in the same way, even if the action (or test) does not seem rational. This session will focus on the predictably irrational nature of microbiology (from the perspective of both testing and results), including case studies on disinfectant efficacy evaluation and recovery of an anaerobic microorganisms from an aerobic aseptic process simulation.

1:15 p.m. – 1:45 p.m.
Sterility Test Recoveries and Process Simulation Design
Kenneth Boone,
Associate Director, Sterile & Microbiology Quality Assurance, Merck & Co., Inc.

1:45 p.m. – 2:15 p.m.
Principles to Consider for Setting Appropriate Bioburden Sample Hold Times
Gretchen Brunner, Scientist, QC Science and Technology, Sanofi and Mark J. Kapeckas, Biologics Corporate Quality Global Program Manager, Sanofi Biologics

2:15 p.m. – 2:45 p.m.
Disinfectant Efficacy: Expect the Unexpected
Jeffrey W. Heiser, Director, Microbiology, Boston Analytical

2:45 p.m. – 3:15 p.m.
Questions and Answers/Discussion

3:15 p.m. – 4:00 p.m.
Refreshment Break and Poster Presentations in Exhibit Hall

4:00 p.m. – 5:30 p.m.
P4: Future Leaders
Moderator: Kim Sobien, Principal Sterility Assurance Engineer, PETNET Solutions | A Siemens Company

Solving regulatory and process problems in the small world of microbiology can seem overwhelming in the grand scheme of product control and quality. Yet sharing of these challenges by the leaders who have experienced them first hand will ensure future success. This session will include four exciting case studies of problem resolution, project implementation, or deficiency awareness from the front lines of the microbiology laboratory or product review division.

4:00 p.m. – 4:15 p.m.
Free Range Facility Parenting: Challenges in Establishing Contamination Control, Environmental Monitoring, and Microbiological Testing Strategies for CAR T Therapies
Joseph R. Sondej, Associate Director, QC Microbiology, Celgene

4:15 p.m. – 4:30 p.m.
It’s A Small World After All:  Microbial Biogeography of a Manufacturing Facility
Emily Elizabeth Castelloe,
Quality Operations Summer Worker, Pfizer Inc.

4:30 p.m. – 4:45 p.m.
Shedding Light on your Water System: Implementation of an Online Water Bioburden Analyzer
Brian H. Fitch, MPH, QC Associate III, Biogen

4:45 p.m. – 5:00 p.m.
Common Deficiencies for Drug Substance Manufacturing
María José López Barragán, PhD, Microbiologist, CDER, FDA

5:00 p.m. – 5:30 p.m.
Questions and Answers/Discussion

Wednesday, October 17

7:00 a.m. – 12:15 p.m.
Registration Open

7:00 a.m. – 8:30 a.m.
Continental Breakfast

7:15 a.m. – 8:15 a.m.
Breakfast Roundtable
Moderator: Julie Barlasov-Brown, MBA, Associate Director Sterile and Microbiology QA, Merck & Co., Inc.  

8:30 a.m. – 10:00 a.m.
P5: USP Updates
Moderator: Radhakrishna S. Tirumalai, PhD, Principal Scientific Liaison, US Pharmacopeial Convention

Compatible with its overall mission, the role of USP in microbiology and sterility assurance is to develop public standards pertaining to microbiology that, along with other requirements, ensure the consistent quality of products. This session will provide an overview on current and proposed activities of the USP General Chapters-Microbiology Expert Committee, with emphasis on revisions to existing chapters and new chapter proposals; discussion of a proposed new chapter proposal on a test for absence of B.cepacia complex; and, discussion of bioburden resistance in materials being terminally sterilized  and a simple method to  determine this.

8:30 a.m. – 8:50 a.m.
Current Activities of the USP Microbiology Expert Committee
David Hussong, PhD, Chief Technical Officer, Eagle

8:50 a.m. – 9:10 a.m.
Burkholderia Cepacia – Prominent Recalls, Screening Methods, and Controls
Tony Cundell, PhD, Principal Consultant, Microbiological Consulting, LLC
 
9:10a.m. – 9:30 a.m.
Estimating Microbial Resistance to Sterilization: The Boil Test
James Agalloco, President, Agalloco & Associates Inc.

9:30 a.m. – 10:00 a.m.
Questions and Answers/Discussion

10:00 a.m. – 10:30 a.m.
Refreshment Break

10:30 a.m. – 12:00 p.m.
P6: Ask the Regulators
Moderator: Amy McDaniel, PhD, Microbiologist, CDER, FDAand John W. Metcalfe, PhD, Quality Assessment Lead, CDER, FDA 

Panel Discussion
Justin A. Boyd,
Investigator, ORA, FDA
Patricia F. Hughes Troost, PhD, Acting Branch Chief, Division of Microbiology Assessment, CDER, FDA (Invited)
Stephen E. Langille, PhD, Acting Division Director, Division of Microbiology Assessment, CDER, FDA
Laurie P. Norwood, Deputy Director, Division of Manufacturing Product Quality, OCBQ, CBER, FDA
Kimberly L. Schultz, Biologist, CBER, FDA (Invited)

12:00 p.m.
Closing Remarks from the Conference Co-Chair
Amy McDaniel, PhD, Microbiologist, CDER, FDA


Conference and Workshop Registration | October 15-18

Member

By August 4, 2018
$3,340

After August 4, 2018
$4,240

Non-member

By August 4, 2018
$3,819

After August 4, 2018
$4,719


Conference Registration | October 15-17

Member

By August 4, 2018
$1,995

After August 4, 2018
$2,595

Non-member

By August 4, 2018
$2,274

After August 4, 2018
$2,874


Government/Health Authority/Academic

Member

By August 4, 2018
$700

After August 4, 2018
$700

Non-member*

By August 4, 2018
$800

After August 4, 2018
$800


Student

Member

By August 4, 2018
$280

After August 4, 2018
$280

Non-member*

By August 4, 2018
$310

After August 4, 2018
$310


Young Professional Member †

Member

By August 4, 2018
$998

After August 4, 2018
$1,298


One Day Only Fee

Monday/Tuesday Only

PDA Member
$1,238

Nonmember
$1,350

All prices in US dollars.

* For this member type or discounted rate, online registration is not available and must be faxed in.

Please note: In order to receive the prevailing registration rate, your registration(s) must be received by PDA by 5:00 p.m. ET on or before the date noted.

Please read PDA's confirmation, substitution, refund, and photo release policies for this workshop and course.

Group Registration Discount

Register 3 people from the same organization as a group (at the same time) for the Conference or Workshop and receive the 4th registration free. Other discounts cannot be applied.

Special Dietary Requirements

Please let us know if you have any special dietary requirement we may assist you with. Please contact us at registration@pda.org for help.

CONFIRMATION: A letter of confirmation will be sent to you once payment is received. You must have this written confirmation to be considered enrolled in a PDA event. Please allow one week for receipt of confirmation letter. If you have submitted a purchase order or requested an invoice please be advised that a credit card guarantee is needed. Please be advised that if your payment or written cancelation notice is not received by August 16, 2018 your credit card will be charged the prevailing rate.

SUBSTITUTIONS: If you are unable to attend, substitutions can be made at any time, including onsite for a fee of $200. If you are a non-member substituting for a member, you will be required to pay the difference non-member fee. If you are pre-registering as a substitute attendee, indicate this on the registration form.

REFUNDS: Refund requests must be in writing and faxed to +1 (301) 986-1093. (Emails and phone messages are not accepted). Refunds for Full Conference, Workshops and Events: If your written request in received on or before August 16, 2018, you will receive a full refund minus a $200 processing fee. After that time, no refunds or credit requests will be approved. Onsite registrants are not guaranteed to receive Conference materials until all advanced registered attendees receive them. PDA reserves the right to modify the material or speakers/instructors without notice or to cancel an event. If an event must be canceled, registrants will be notified by PDA in writing as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancelation. For more details, contact PDA at info@pda.org or +1 (301) 656-5900.

PLEASE NOTE: Photo ID will be required in order to pick up badge materials on-site. This important security procedure will prevent anyone other than the registrant from picking up their badge and materials.

RECORDING/PHOTO RELEASE: By registering for these events, I authorize PDA to record and photograph me and to use the recordings/photographs in all formats and media for any purpose, including for education, marketing and trade purposes. I hereby release PDA from all claims arising out of the use of the recordings/photographs, including without limitation all claims for compensation, libel, invasion of privacy or violation of copyright ownership. Tape recordings are prohibited at all PDA Conferences.

Bethesda North Marriott HotelBethesda North Marriott Hotel & Conference Center
5701 Marinelli Rd
North Bethesda, MD 20852
Phone: +1 (301) 822-9200

Rate: Single: $269.00, plus applicable state and local taxes.

Cut Off Date: Monday, September 17, 2018 (Rooms must be secured by this date in order to receive the PDA rate). Rates are guaranteed until the PDA block of rooms are sold out on a first come basis.

Hotel Accommodations

To make reservations at the Marriott Bethesda North Hotel and Conference Center, please call the Hotel at +1 (301) 822-9200 and reference the PDA Meeting to receive the PDA group rate. Check in time is 4:00 p.m. and check out time is 12:00 p.m.

Individual Cancellation

Please be aware that obtaining and canceling hotel reservations is the responsibility of the meeting registrant. Individuals will be responsible for payment of their own cancellation fees. The cancellation policy is 6:00 p.m. on the date of arrival otherwise specified on your reservation information.

Amenities

The Marriott Bethesda North Hotel & Conference Center is adjacent to the White Flint METRO Station on the RED line offering easy access to Rockville, Bethesda, Washington D.C. and Northern Virginia. All 220 guest rooms and suites provide high-speed Internet, upgraded Marriott Revive bedding, coffee makers, hair dryers, iron, and an ironing board. This hotel has a smoke-free policy and no pets are allowed.

Travel

Area Airports
Reagan National Airport (DCA) is approximately 20 miles from the hotel and all major carriers service this airport. Two other airports in the vicinity are both serviced by all major carriers: Dulles International, 24 miles away, and Baltimore-Washington International, 34 miles away.

Ground Transportation
Taxi fares from DCA are approximately $55 one way, not including tip, and will take about 30 minutes. One way taxi fares from Dulles is approximately $55 and from BWI about $75.

Driving
Bethesda North Marriott is located on Marinelli Road off of Rockville Pike in Rockville.

Metro
The Bethesda North Marriott is located on the RED line at the White Flint Station.

Hotel Parking
$15 Self Parking

Sponsorship and Exhibit Opportunities are Available!

The 13th Annual PDA Microbiology Conference offers exciting and unique sponsorship and exhibition packages designed to strengthen brand image, increase visibility, and help you connect with industry leaders. This Conference will bring together industry experts from microbiology, manufacturing, laboratories, compliance, quality, research and development, engineering, validation, regulatory affairs as well as executives, managers, scientists, technicians and analysts.

At this conference you will be exposed to high quality attendees from a variety of manufacturing companies – making this a must attend meeting. In addition, high profile sponsorships are available for lanyards, notepads, audience response systems, tote bags, pens, refreshment breaks, lunch and networking reception. We’ll create a customized sponsorship to fit your needs and budget.

For more information about exhibit and sponsorship opportunities, please contact:

David Hall, Vice President, Sales

Tel: +1 (301) 760-7373
Cell: +1 (240) 688-4405
Fax: +1 (301) 986-0296
Email: hall@pda.org

Register Now
https://store.pda.org/Meetings/Login.aspx?ID=3990

Directions